How exactly does cosentyx affect the immune system?

How does Cosentyx suppress immune signaling?

Cosentyx (secukinumab) attaches to interleukin-17A (IL-17A) and blocks its binding to receptors on cells. This stops IL-17A from recruiting neutrophils and releasing inflammatory cytokines that keep psoriatic and ankylosing spondylitis inflammation going.

Can Cosentyx raise infection risk?

By interfering with IL-17A, Cosentyx weakens the body’s defense against certain bacteria and fungi. Clinical data show higher rates of upper respiratory infections, candida, and occasional serious infections among patients compared with placebo.

What happens if you stop taking Cosentyx?

IL-17A levels rebound quickly after discontinuation, restoring inflammatory pathways. Disease symptoms often return within weeks rather than months, so many patients keep continuous treatment to maintain control.

Does Cosentyx leave permanent immune changes?

Current evidence indicates no long-term alteration of immune function after discontinuation. The monoclonal antibody has a half-life of approximately 25–28 days, and its effects fade as it clears from the body.

Why are companies challenging Cosentyx patents?

Several generic and biosimilar makers have filed patent challenges against Novartis, aiming to launch earlier versions of secukinumab.